These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21725212

  • 1. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 01; 12(3):229-38. PubMed ID: 21725212
    [Abstract] [Full Text] [Related]

  • 2. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
    Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 01; 12(3):239-51. PubMed ID: 21725213
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P.
    J Cell Physiol; 2013 Oct 01; 228(10):1996-2005. PubMed ID: 23674352
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.
    Cancer Biol Ther; 2009 Dec 01; 8(24):2406-16. PubMed ID: 20038816
    [Abstract] [Full Text] [Related]

  • 8. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.
    J Biol Chem; 2007 Oct 12; 282(41):29831-46. PubMed ID: 17698840
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 10. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S, Tripathi N, Preet R, Siddharth S, Nayak A, Bharatam PV, Kundu CN.
    Oncotarget; 2017 Jan 03; 8(1):248-267. PubMed ID: 27542249
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N, Takei Y, Nobori T, Ito M.
    Int J Oncol; 2013 Jan 03; 42(1):101-8. PubMed ID: 23123700
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
    Fernando J, Sancho P, Fernández-Rodriguez CM, Lledó JL, Caja L, Campbell JS, Fausto N, Fabregat I.
    J Cell Physiol; 2012 Apr 03; 227(4):1319-25. PubMed ID: 21604268
    [Abstract] [Full Text] [Related]

  • 13. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L, Wang Y, Zheng H, Zhang D, Wu X, Sun G, Yang T.
    J Chemother; 2017 Jun 03; 29(3):179-188. PubMed ID: 28067150
    [Abstract] [Full Text] [Related]

  • 14. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X.
    Eur J Cancer; 2010 Mar 03; 46(4):836-50. PubMed ID: 20071162
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 03; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 16. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul 03; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

  • 17. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
    Wang C, Qi R, Li N, Wang Z, An H, Zhang Q, Yu Y, Cao X.
    J Biol Chem; 2009 Jun 12; 284(24):16183-16190. PubMed ID: 19376776
    [Abstract] [Full Text] [Related]

  • 18. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
    Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS.
    Cancer Cell; 2007 Jul 12; 12(1):66-80. PubMed ID: 17613437
    [Abstract] [Full Text] [Related]

  • 19. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
    Zhang B, Shan H, Li D, Li ZR, Zhu KS, Jiang ZB, Huang MS.
    Oncol Rep; 2011 Feb 15; 25(2):461-8. PubMed ID: 21152876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.